{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:12:07Z","timestamp":1785604327264,"version":"3.56.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T00:00:00Z","timestamp":1392076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pirarubicin tetrahydropyranyl adriamycin (THP\u2010ADR) is an analogue of doxorubicin. This agent exhibits activity against some doxorubicin\u2010resistant cell lines. We performed a phase II study of biweekly THP\u2010COP [50\u2009mg\/m<jats:sup>2<\/jats:sup> pirarubicin, 750\u2009mg\/m<jats:sup>2<\/jats:sup> cyclophosphamide, 1.4\u2009mg\/m<jats:sup>2<\/jats:sup> vincristine (2.0\u2009mg maximum) on day 1, and 100\u2009mg\/body predonisolone on days 1\u20135] in patients with peripheral T\u2010cell lymphoma (PTCL). Seventeen patients with newly diagnosed PTCL were enrolled. Histological diagnoses were of PTCL, not otherwise specified (<jats:italic>n<\/jats:italic>\u2009=\u20095), or angioimmunoblastic T\u2010cell lymphoma (<jats:italic>n<\/jats:italic>\u2009=\u200912). All diagnostic specimens including those of the historical control group were centrally reviewed by hematological pathologists. All patients received six cycles of biweekly THP\u2010COP. The patient group included 13 male and 4 female patients, with a median age of 62\u2009years. The median follow\u2010up time in surviving patients was 30\u2009months. Overall response rate was 94% with 15 cases of complete remission (88%). The 3\u2010year progression\u2010free survival and overall survival rates were 57% and 75%, respectively. The most frequent adverse events associated with biweekly THP\u2010COP were leukocytopenia (100%), neutropenia (100%), and lymphopenia (100%), followed by alopecia (92%) and anaemia (88%). All of these occurred only transiently, and the patients subsequently recovered. Biweekly THP\u2010COP is a safe and promising therapy for patients with newly diagnosed PTCL. This study is registered in a public database (UMIN000010485). Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2136","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T10:59:55Z","timestamp":1392202795000},"page":"9-14","source":"Crossref","is-referenced-by-count":15,"title":["Biweekly THP\u2010COP therapy for newly diagnosed peripheral T\u2010cell lymphoma patients"],"prefix":"10.1002","volume":"33","author":[{"given":"Naoto","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Tsuyama","sequence":"additional","affiliation":[{"name":"Division of Pathology, The Cancer Institute Japanese Foundation for Cancer Research  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, The Cancer Institute Japanese Foundation for Cancer Research  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Pathology, The Cancer Institute Japanese Foundation for Cancer Research  Tokyo Japan"},{"name":"Pathology Project for Molecular Targets, The Cancer Institute Japanese Foundation for Cancer Research  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokosuka City Hospital  Yokosuka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Shizuoka Red Cross Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City University Medical Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City University Medical Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Koharazawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Yamato Municipal Hospital  Yamato Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Immunology Fujisawa City Hospital  Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Kanagawa Cancer Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City University Medical Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-374371"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22507"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.1085"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.1082"},{"key":"e_1_2_6_10_1","first-page":"1462","article-title":"4\u2032\u2010O\u2010Tetrahydropyranyladriamycin as a potential new antitumor agent","volume":"42","author":"Tsuruo T","year":"1982","journal-title":"Cancer Res"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.515"},{"key":"e_1_2_6_12_1","first-page":"71","article-title":"Cellular uptake and cytostatic activity of pirarubicin (THP) in T\u2010lymphoma cells","volume":"48","author":"Sato Y","year":"1999","journal-title":"J New Remedies Clinics"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.03147"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq619"},{"key":"e_1_2_6_16_1","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0469-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq635"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0351-4"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08634.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01411.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp211"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2131"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1996.tb02122.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1515.bloodjournal8641515"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1995"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1182\/blood.V89.10.3795","article-title":"Expression of the multidrug resistance\u2010associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay","volume":"89","author":"Zhan Z","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90187-2"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2136","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:52:52Z","timestamp":1696499572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1002\/hon.2136"],"URL":"https:\/\/doi.org\/10.1002\/hon.2136","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]}}}